Viscoli C, Castagnola E, Fioredda F, Ciravegna B, Barigione G, Terragna A
First Department of Infectious Diseases, University of Genoa, Italy.
Antimicrob Agents Chemother. 1991 Feb;35(2):365-7. doi: 10.1128/AAC.35.2.365.
Fluconazole, a new triazole derivative, was evaluated in a pilot study of 34 episodes of candidiasis in 24 children. All the patients had predisposing conditions, such as human immunodeficiency virus infection, cancer, organ or bone marrow transplantation, neonatal age and malnutrition, and obstructive uropathy. The drug was administered at 6 mg/kg (body weight) once daily either orally or intravenously. Two patients with fungemia due to Candida parapsilosis required an increased dosage of 12 mg/kg. Clinical and microbiological success was achieved in 30 of 34 cases (88%). Drug-related transaminase increases were observed in two cases (6%). Fluconazole may represent an effective alternative to amphotericin B in the treatment of candidiasis in children. Comparative trials are necessary to assess optimal dosages and efficacy.
氟康唑是一种新型三唑衍生物，在一项针对24名儿童的34例念珠菌病的初步研究中进行了评估。所有患者都有易感因素，如人类免疫缺陷病毒感染、癌症、器官或骨髓移植、新生儿期和营养不良以及梗阻性尿路病。该药物以6毫克/千克（体重）的剂量每日一次口服或静脉给药。两名因近平滑念珠菌引起真菌血症的患者需要将剂量增加到12毫克/千克。34例中有30例（88%）临床和微生物学治疗成功。有两例（6%）观察到与药物相关的转氨酶升高。在儿童念珠菌病的治疗中，氟康唑可能是两性霉素B的一种有效替代药物。需要进行比较试验来评估最佳剂量和疗效。
